Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Position Lifted by Principal Financial Group Inc.

Principal Financial Group Inc. boosted its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 30.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 102,469 shares of the company’s stock after acquiring an additional 23,843 shares during the period. Principal Financial Group Inc. owned about 0.07% of Xeris Biopharma worth $292,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in XERS. Barclays PLC boosted its position in shares of Xeris Biopharma by 87.8% during the third quarter. Barclays PLC now owns 324,472 shares of the company’s stock worth $925,000 after buying an additional 151,685 shares during the period. Geode Capital Management LLC boosted its holdings in Xeris Biopharma by 2.9% during the third quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock worth $9,502,000 after buying an additional 93,091 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Xeris Biopharma during the third quarter worth $44,000. SG Americas Securities LLC lifted its stake in Xeris Biopharma by 188.5% during the third quarter. SG Americas Securities LLC now owns 60,202 shares of the company’s stock valued at $172,000 after buying an additional 39,335 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in Xeris Biopharma during the 3rd quarter valued at $3,197,000. 42.75% of the stock is currently owned by institutional investors.

Xeris Biopharma Trading Down 1.9 %

Shares of NASDAQ:XERS opened at $3.54 on Tuesday. The business’s 50 day moving average is $3.34 and its 200-day moving average is $2.88. The firm has a market capitalization of $527.75 million, a PE ratio of -7.87 and a beta of 2.62. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.69 and a 1-year high of $3.87.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on XERS shares. Piper Sandler downgraded shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price objective on the stock. in a research report on Monday, November 11th. HC Wainwright lifted their target price on shares of Xeris Biopharma from $6.00 to $6.60 and gave the stock a “buy” rating in a report on Monday, November 11th.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.